Redaelli Alberto, Bell Christopher, Casagrande Jodie, Stephens Jennifer, Botteman Marc, Laskin Benjamin, Pashos Chris
Global Outcomes Research, Pharmacia Corporation, Milan, Italy.
Expert Rev Anticancer Ther. 2004 Feb;4(1):85-96. doi: 10.1586/14737140.4.1.85.
Chronic myelogenous leukemia represents 7-20% of all leukemia cases, with a worldwide incidence projected at less than one to two per 100,000 people. Approximately 85% of patients are diagnosed with chronic-phase chronic myelogenous leukemia and up to 40% are asymptomatic. Treatment strategies include chemotherapy, interferon-alpha therapy, transplantation (bone marrow/stem cell transplant) and imatinib mesylate (Gleevec), with the impact of treatment best realized during the chronic phase of the disease. Only transplantation has been clinically demonstrated to eradicate the Philadelphia chromosome, alter the natural course of the disease and cure patients diagnosed with chronic myelogenous leukemia. Interferon-alpha is currently considered for first-line treatment, however, the recent introduction of targeted therapy may change clinical practice. Ongoing research focused on new drug combinations and target therapies may eventually expand the armamentarium available to cure this disease.
慢性粒细胞白血病占所有白血病病例的7%-20%，全球发病率预计低于每10万人1至2例。约85%的患者被诊断为慢性期慢性粒细胞白血病，高达40%的患者无症状。治疗策略包括化疗、α干扰素治疗、移植（骨髓/干细胞移植）和甲磺酸伊马替尼（格列卫），治疗效果在疾病慢性期最为显著。只有移植已在临床上被证明可消除费城染色体、改变疾病自然进程并治愈被诊断为慢性粒细胞白血病的患者。α干扰素目前被视为一线治疗药物，然而，靶向治疗的近期引入可能会改变临床实践。专注于新药联合和靶向治疗的正在进行的研究最终可能会扩大可用于治愈这种疾病的武器库。
